Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GRN-1201 + GM-CSF in resected melanoma
NCT02696356Phase 1Completed
- Sponsor
- BrightPath Biotherapeutics Co., Ltd.
- Start
- Apr 2016
- Primary completion
- Mar 2018
- Modality
- Peptides, Therapeutic Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label trial of grn-1201 in melanoma (3 cohorts), sponsored by BrightPath Biotherapeutics Co., Ltd. Primary endpoint: Number of Participants With Treatment-Related Adverse Events at 16 weeks. Started Apr 2016; status: completed.
02
Drugs
grn-1201
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT02696356.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02696356.